Why Is PDL BioPharma (PDLI) Up 4.6% Since Last Earnings Report?

- Advertisement -
- Advertisement -
- Advertisement -
- Advertisement -

It has been about a month since the last earnings report for PDL BioPharma (PDLI). Shares have added about 4.6% in that time frame, underperforming the S&P 500.

Will the recent positive trend continue leading up to its next earnings release, or is PDL BioPharma due for a pullback? Before we dive into how investors and analysts have reacted as of late, let’s take a quick look at its most recent earnings report in order to get a better handle on the important drivers.

 

 

It has been about a month since the last earnings report for PDL BioPharma (PDLI). Shares have added about 4.6% in that time frame, underperforming the S&P 500.

Will the recent positive trend continue leading up to its next earnings release, or is PDL BioPharma due for a pullback? Before we dive into how investors and analysts have reacted as of late, let’s take a quick look at its most recent earnings report in order to get a better handle on the important drivers.

PDL BioPharmaMisses on Q4 Earnings, To Dissolve by Year-End

PDL BioPharma reported earnings of 3 cents per share (including the impact of stock-based compensation expense) in the fourth quarter of 2019, missing the Zacks Consensus Estimate of 5 cents. The bottom line was also lower than the year-ago earnings of 10 cents.

The company reported total revenues of a negative $5.8 million in the quarter against the positive $46 million generated in the prior year. The negative revenues were due to a change in the fair value of royalty rights.

PDL announced a plan to dissolve the company by the end of 2020.

It has been about a month since the last earnings report for PDL BioPharma (PDLI). Shares have added about 4.6% in that time frame, underperforming the S&P 500.

Will the recent positive trend continue leading up to its next earnings release, or is PDL BioPharma due for a pullback? Before we dive into how investors and analysts have reacted as of late, let’s take a quick look at its most recent earnings report in order to get a better handle on the important drivers.

PDL BioPharmaMisses on Q4 Earnings, To Dissolve by Year-End

PDL BioPharma reported earnings of 3 cents per share (including the impact of stock-based compensation expense) in the fourth quarter of 2019, missing the Zacks Consensus Estimate of 5 cents. The bottom line was also lower than the year-ago earnings of 10 cents.

The company reported total revenues of a negative $5.8 million in the quarter against the positive $46 million generated in the prior year. The negative revenues were due to a change in the fair value of royalty rights.

PDL announced a plan to dissolve the company by the end of 2020.

Home of Science
Follow me

- Advertisement -

Discover

Sponsor

Latest

Fishing row: France delays sanctions as talks over access continueon November 2, 2021 at 8:20 am

Paris has stepped back from a threat to block British fishing boats from its ports from midnight.Image source, PA MediaFrance will delay retaliatory measures...

Know the Mesothelioma Causes

The causes of mesothelioma remain unknown as of this writing. However, there is strong evidence that exposure to asbestos and its fibres causes this...

Kabul airport attack: What do we know?on August 26, 2021 at 6:24 pm

The bombings came hours after warnings to citizens to stay away from the airport, due to an imminent threat.

Uighurs: China sanctions UK MPs over abuses responseon March 26, 2021 at 3:03 am

It comes after the UK government took action over human rights abuses against the Uighur minority.The nine people facing sanctions are Tory MPs Sir...

Dressing Up With Business Casual Clothing

Dressing Up With Business Casual ClothingBusiness casual is an ambiguous term, usually described as professional or casual wear with subtle, smart aspects of...
Home of Science
Follow me